IgG4-Related Systemic Disease Features and Treatment Response in a French Cohort: Results of a Multicenter Registry Mikael Ebbo, MD, Laurent Daniel, MD, PhD, Michel Pavic, MD, Pascal Se`ve, MD, PhD, Mohamed Hamidou, MD, PhD, Emmanuel Andres, MD, Ste´phane Burtey, MD, PhD, Laurent Chiche, MD, Jacques Serratrice, MD, PhD, Ma¨ıte´ Longy-Boursier, MD, PhD, Marc Ruivard, MD, PhD, Julien Haroche, MD, PhD, Bertrand Godeau, MD, Anne-Be´renge`re Beucher, MD, Jean-Marie Berthelot, MD, Thomas Papo, MD, Jean-Loup Pennaforte, MD, Audrey Benyamine, MD, Noe´mie Jourde, MD, Ce´dric Landron, MD, Pascal Roblot, MD, PhD, Olivier Moranne, MD, PhD, Christine Silvain, MD, Brigitte Granel, MD, Fanny Bernard, MD, Veronique Veit, MD, Karin Mazodier, MD, Emmanuelle Bernit, MD, Hugues Rousset, MD, Jose´ Boucraut, MD, PhD, Jean-Jacques Boffa, MD, PhD, Pierre-Jean Weiller, MD, Gilles Kaplanski, MD, PhD, Pierre Aucouturier, PhD, Jean-Robert Harle´, MD, and Nicolas Schleinitz, MD INTRODUCTION Abstract: IgG4-relatedsystemicdiseaseisnowrecognizedasasystemicdiseasethatmayaffectvariousorgans.Thediagnosisisusually madeinpatientswhopresentwithelevatedIgG4inserumandtissue IgG4 isundernormalconditionsoneofthelessabundantIgG infiltrationofdiseasedorgansbynumerousIgG4+plasmacells,inthe subclasses in blood. Because IgG4 poorly binds Fc (constant absenceofvalidateddiagnosiscriteria.Wereporttheclinical,laboratory, fragment) receptorsand does notactivate the complement clasand histologic characteristics of 25 patients from a French nationwide sical pathway, itsroleinhumoralimmuneresponsesisunclear. cohort.Wealsoreportthetreatmentoutcomeandshowthatdespitethe Some reports suggest that the relative expression of the IgG4 efficacyofcorticosteroids,asecond-linetreatmentisfrequentlynecessary. isotypeamongantibodiesincreaseswithiterativeantigenicchalTheclinicalfindingsinourpatientsarenotdifferentfromtheresultsof lenges,1andthatIgG4displaysantiinflammatoryproperties.19A previous reports from Eastern countries. Our laboratory and histologic polyclonal and moderate increase of blood IgG4 has been refindings,however,suggest,atleastinsomepatients,amorebroadpoly- portedinallergicdisease,parasiticinfection,andseveralinflamclonalBcellactivationthantheskewedIgG4switchpreviouslyreported. matory or lymphoproliferative conditions.2 To our knowledge, These observations strongly suggest the implication of a T-cell depen- the relation between inflammatory organ lesions and elevated dentB-cellpolyclonalactivationinIgG4-relatedsystemicdisease,prob- IgG4 levels was first reported by Hamano et al8 in patients ablyatleastinpartunderthecontrolofThelperfollicularcells. with ‘‘autoimmune’’ pancreatitis. Of note, hypergammaglobulinemia was noted several years before in such conditions by (Medicine2012;91:49Y56) Sarles et al,16 although they did not assess the repartition of IgG subclasses. Since these first descriptions, several types of Abbreviations: Fc = constant fragment, FITC = fluorescein inflammatoryorganinvolvementhavebeenrecognizedasmaniisothiocyanate,IgG4-RSD=IgG4-relatedsystemicdisease,mAb= festationsofIgG4-relatedsystemicdisease(IgG4-RSD).9Howmonoclonalantibody,SD=standarddeviation,Th2=Thelper2. ever, few series have been reported from Western countries. FromUniversite´ delaMe´diterrane´eAix-MarseilleII(ME,LD,SB,LC,JS, re´fe´rencedesCytope´niesauto-immunes(B.Godeau),HoˆpitalHenriMondor, AB,NJ,B.Granel,JB,PJW,GK,JRH,NS),Marseille;ServicedeMe´decine AssistancePublique-HoˆpitauxdeParis,Universite´Paris12,Cre´teil;Servicede Interne(ME,LC,VV,KM,EB,GK,JRH,NS),ServicedeNe´phrologie(SB, Me´decineInterne(ABB),CentreHospitalierUniversitaired’Angers,Angers; NJ),andLaboratoired’Immunologie(JB),HoˆpitaldelaConception,Assis- ServicedeMe´decineInterne(TP),HoˆpitalBichat-ClaudeBernard,Assistance tancePublique-HoˆpitauxdeMarseille,Marseille;Serviced’AnatomiePatho- Publique-HoˆpitauxdeParis,Universite´ Paris7,Paris;ServicedeMe´decine logiqueetdeNeuropathologie(LD),andServicedeMe´decineInterne(JS, Interne(JLP),HoˆpitalRobertDebre´,CentreHospitalierUniversitairedeReims, AB,PJW),HoˆpitaldelaTimone,AssistancePublique-HoˆpitauxdeMarseille, Reims;ServicedeMe´decineInterne(CL,PR),andServicedeGastroente´rMarseille;ServicedeMe´decineInterne-Oncologie(MP),HoˆpitalD’instruction ologie(CS),CentreHospitalierUniversitairelaMiletrie,Poitiers;Servicede desArme´esDesgenettes,Lyon;ServicedeMe´decineInterne(PS),Hoˆtel-Dieu, Ne´phrologie(OM),CentreHospitalierUniversitairedeNice,Nice;Servicede HospicesCivilsdeLyon,Universite´ClaudeBernardLyon1,Lyon;Servicede Me´decineInterne(B.Granel,FB),HoˆpitalNord,AssistancePublique-Hoˆpitaux Me´decineInterne(MH), and ServicedeRhumatologie (JMB),Hoˆtel Dieu, deMarseille,Marseille;ServicedeMe´decineInterne(HR),CentreHospitalier Centre Hospitalier Universitaire de Nantes, Nantes; Service de Me´decine Lyon-Sud,HospicesCivilsdeLyon,PierreBenite;LaboratoireNeurobiologie Interne(EA),CliniqueMe´dicaleB,CentreHospitalierUniversitairedeStras- des Interactions Cellulaires et Neurophysiopathologie (NICN) (JB), CNRS bourg,Strasbourg;Inserm U897,ServicedeMe´decineInterneetTropicale UMR6184,Faculte´deMe´decine,Universite´Aix-Marseille,Marseille;Service (MLB),HoˆpitalSaint-Andre´,CentreHospitalierUniversitairedeBordeaux, deNe´phrologie(JJB),HoˆpitalTenon,AssistancePublique-HoˆpitauxdeParis, Universite´Bordeaux2Victor-Segalen,Bordeaux;ServicedeMe´decineInterne Universite´PierreetMarieCurie,Paris;INSERM,UMR-S938,HoˆpitalSaint- (MR),HoˆtelDieu,CentreHospitalierUniversitairedeClermont-Ferrand;Ser- Antoine(PA),Universite´PierreetMarieCurie,Paris;andCentred’ImmunovicedeMe´decineInterneetCentredeRe´fe´rencedesMaladiesauto-immuneset logie de Marseille-Luminy (NS), Universite´ de la Me´diterrane´e, case 906, syste´miquesrares(JH),HoˆpitalPitie´-Salpeˆtrie`re,AssistancePublique-Hoˆpitaux CampusdeLuminy,Marseille,France. deParis,Universite´Paris6,Paris;ServicedeMe´decineInterneetCentrede Theauthorshavenofundingorconflictsofinteresttodisclose. Copyright*2012byLippincottWilliams&Wilkins Reprints:NicolasSchleinitz,MD,ServicedeMe´decineInterne,CHU ISSN:0025-7974 Conception,AP-HM,13385MarseilleCedex05,France DOI:10.1097/MD.0b013e3182433d77 (e-mail:nicolas.schleinitz@ap-hm.fr). & 49 Medicine Volume91,Number1,January2012 www.md-journal.com
& Ebboetal Medicine Volume91,Number1,January2012 The diagnosis of IgG4-RSD or IgG4+ multiorgan lymphopro- InclusionCriteria liferative syndrome (MOLPS)11 is now used for patients pre- There is no international consensus regarding IgG4-RSD senting with elevated polyclonal IgG4 blood levels and organ diagnostic criteria to date. In the current study, patients were involvement including sclerosing pancreatitis, sclerosing cho- considered to have IgG4-RSD if they had 1) sclerosing and langitis, retroperitoneal fibrosis, mediastinal fibrosis, Ku¨ttner inflammatoryinvolvement of 1or more organ, including scletumor,andinflammatorypseudotumors.Todatetherearenoin- rosing pancreatitis, sclerosing cholangitis, inflammatory pseuternationallyrecognizeddiagnosticcriteriaforIgG4-RSD.Crite- dotumors, retroperitoneal or mediastinal fibrosis, interstitial riahavebeenproposedforautoimmunepancreatitis,andacutoff nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis value of 1.35 g/L serum IgG4 (by single radial immunodiffu- (MikuliczdiseaseandKu¨ttnertumor),inflammatoryaorticansionornephelometry)resultedinahighrateofspecificity(97%) eurysm, lymphadenopathy, or other inflammatory conditions; and sensitivity (95%), allowing the differentiation of autoim- and 2) elevated serum IgG4 (91.35 g/L) (measured by nephemune pancreatitis from other pancreatic diseases.6Y8,12,14 This lometry or by ELISA); with 3) histopathologic features of cutoff value has been extended for thediagnosisofIgG4-RSD. fibrosis and/or lymphocytic and polyclonal plasma cell infilCharacteristic pathologic features include an inflammatory cell tration (and IgG4+ plasma cells on immunohistology when infiltrate dominated by lymphocytes and plasmocytes some- performed);and4)exclusionofotherdiseases. times with lymphoid follicle formations. Other characteristic findings are fibrosis with a storiform pattern and obliterative EvaluationofTreatmentResponse phlebitis. A marked IgG4+ plasma cell infiltration with an In the clinical data entry form and the follow-up form, IgG4+/IgG+plasmacellratio90.4onimmunohistology,usually physicians were asked to answer yes or no to the following observed in these patients, has also been proposed to ascertain questionsregardingthediseaseevolution:Didtheclinicalstatus thediagnosis.5 improve? Did the IgG4 level significantly decrease? Did the BoththemechanismsofIgG4plasmacellinfiltrationand radiologic abnormalities improve? Treatment was considered IgG4 production, and the role of IgG4 in the disease remain effective if at least 2 of these criteria improved based on the unknown. To better define the characteristics of patients with physician’sevaluation. IgG4-RSD,wecreatedamulticenterregistryinFrance.Wereport here on the clinical, laboratory, and histologic characterHistologicAnalysis isticsof25patients. Tissuebiopsieswereallanalyzedbyconventionalmicroscopy with Masson trichrome and hematoxylin-eosin staining. PATIENTSANDMETHODS When performed, staining by anti IgG, IgG4, IgG3, IgG2 and IgG1-fluorescein isothiocyanate (FITC) monoclonal antibody AscertainmentofPatients (mAb)(allfromTheBindingSite,Birmingham,UK)wereanPatientswereascertainedinseveralways.InFebruary2009, alyzed by immunofluorescence. IgG4+ plasma cell infiltration all members of the French National Society of Internal was assessed by a semi-quantitative evaluation from the paMedicine were sent an e-mail describing characteristics of thologyexamination: no(-), present(+), abundant(++),orinIgG4-RSD and inquiring if they were orhad previouslybeen tense(+++)IgG4+ plasmacellinfiltrate.Whenthenumberof followingpatientswithIgG4-RSD,andiftheywouldagreeto enter them in the registry. Another description of the disease and the registry was presented in June 2009, during the TABLE1. ClinicalFeaturesofPatientsWithIgG4-RSD national congress of the Society. Nephrologists were invited atPresentation to include patients in the registry through an announcement on the website of the French Society of Nephrology. Two No.(%) investigators who were performing serum IgG subclass meaFeature (n=25) surementswereaskedtoprovidethenamesofphysicianswho had sent blood samples from patients with IgG4 elevation Symptom 91.35 g/L in the context of clinical suspicion of IgG4-RSD. Asthenia 14(56) Physicianswere sent a 3-page clinical data entry form request- Weightloss 11(44) ingdetailedinformationonthedemographicandclinicalcharacAbdominalpain 10(40) teristics ofthe patient; the laboratory, radiologic, and histologic Xerostomia 8(32) findings at diagnosis; treatments and corresponding responses; Xerophthalmia 6(24) andthepatients’lateststatus.Thefirstpatientwasregisteredin Coughordyspnea 5(20) February2009,andbetweenthenandOctober2010,25patients wereenteredintotheregistry.InMay2010,a2-pagefollow-up Diarrhea 3(12) form was sent to each physician who had entered patients in Pruritus 3(12) theregistryuptothatdate,requestinginformationonthestatus Fever 3(12) of the patients at their last follow-up and the date of that last Visualdisorder 1(4) follow-up. Examination Lymphadenopathy 11(44) ConstructionofRegistry Jaundice 5(20) To maintain patient anonymity, the only identifying data Salivaryglandswelling 5(20) collectedwerethepatients’initials,birthdate,andsex.Thenames, Hepatomegaly 3(12) addresses,phonenumbers,socialsecuritynumbers,and/orhosAbnormalpulmonaryauscultation 3(12) pitalnumberswerenotprovided.Duplicateentriesfromdifferent Splenomegaly 2(8) physicianswere avoided by cross-checking the patients’ initials Lacrimalglandswelling 1(4) andbirthdates. 50 www.md-journal.com *2012LippincottWilliams&Wilkins
& Medicine Volume91,Number1,January2012 NationwideStudyofIgG4-RelatedSystemicDisease IgG4+ plasmocytes per high-power field or the IgG4+/IgG+ TABLE2. OrganInvolvementofPatientsWithIgG4-RSD plasmacellratiowereavailable,theywerenoted. No.(%) StatisticalAnalysis OrganInvolvement (n=25) IgG4 levels were expressed as geometrical means and Adenopathy 19(76) standarddeviations(SD).CorrelationsofIgG4withIgG1,IgG2, Sclerosingpancreatitis 13(52) and IgG3 levels were performed with the Spearman rank test, Sialadenitis 11(44) usingGraphPadPrismv.4.0. Interstitialnephritis 11(44) Sclerosingcholangitis 8(32) RESULTS Retroperitonealfibrosis 8(32) Aorticinvolvement 6(24) PatientCharacteristics Abdominalaorta 6(24) Among 50 cases reported, 25 patients fulfilled the incluThoracicaorta 3(12) sioncriteriaandwereretainedforthestudy.Mostwererecruited Dacryoadenitis 3(12) through the French Society of Internal Medicine, others from Interstitialpneumonitis 3(12) nephrologists and a few from gastroenterologists and rheumaHypophysitis 2(8) tologists. Among cases excluded from the study (n = 25), 12 Inflammatorypseudotumor 4(16) patientshadtypicalorganinvolvementbutIgG4levelsG1.35g/L, 5patientshadtypicalorganinvolvementandhighserumIgG4 Orbital 1(4) but insufficient available data, and 8 patients had serum IgG4 Hepatic 2(8) levels 91.35 g/L but no characteristic organ involvement and Meningeal 1(4) anotherdiagnosis(Gougerot-Sjo¨grenin2patients,andrelapsing TABLE3. Characteristicsof25PatientsWithIgG4-RSD Associated Patient Age/Sex(yr) IgG4-RSDManifestation Allergy* InflammatoryCondition 1 70/F AIP,IN,hepaticIPT,LN Yes No 2 50/F AIP,orbitalIPT,dacryoadenitis,sialadenitis,LN Yes No 3 54/M RPF No No 4 54/M MeningealIPT No No 5 66/M IN,LN Yes No 6 72/M AIP,SC,IN,LN No No 7 74/F AIP,sialadenitis,LN No Ankylosingspondylarthritis 8 45/M RPF No No 9 72/M AIP,SC,sialadenitis,IN,LN,aortitis No No 10 50/F RPF,mediastinalandpleuralfibrosis,Riedelthyroiditis, No No aortitis,coronaryinflammatorylesions 11 53/F AIP,SC No No 12 61/M RPF,AIP,sialadenitis,LN No No 13 24/F SC,LN,splenomegaly No No 14 56/M IN,ADP,interstitialpneumonitis No No 15 83/M IN,RPF,AIP,sialadenitis,LN,splenomegaly No No 16 26/M Sialadenitis,AIP,SC,LN No No 17 79/F AIP,LN,interstitialpneumonitis No Sarcoidosis 18 50/M IN,sialadenitis,LN,hypophysitis Yes No 19 69/M RPF,aortitis,dacryoadenitis,sialadenitis,LN No Rheumatoidarthritis 20 54/M RPF,aortitis,iliac,carotidandintracerebralinflammatory No No aneurysms,hypophysitis 21 49/M AIP,SC,LN,renalIPT No No 22 69/M AIP,IN,hepaticIPT,LN Yes No 23 41/M Dacryoadenitis,sialadenitis,LN,interstitialpneumonitis Yes Rectocolitis 24 55/M AIP,SC,RPF,aortitis,sialadenitis,renalIPT,LN No Anteriorgranulomatousuveitis? 25 77/M Sialadenitis,IN,pararenalIPT No No Abbreviations:AIP=autoimmunepancreatitis,IN=interstitialnephritis,IPT=inflammatorypseudotumor,LN=lymphnodeinvolvement,RPF= retroperitonealfibrosis,SC=sclerosingcholangitis. *Allergicmanifestationswereallergicrhinitisand/orbronchialasthma. 51 *2012LippincottWilliams&Wilkins www.md-journal.com
& Ebboetal Medicine Volume91,Number1,January2012 polychondritis with membranous glomerulonephritis, HenochScho¨nlein purpura, cystic fibrosis, hypogammaglobulinemia withrecurrentinfectionsandscleritis,eosinophilicfasciitis,and post-streptococcaluveitisintheother6patients).Ofnote,3of the 12 patients with normal IgG4 blood levels presented with typical pathologic findings including IgG4+ plasmocyte infiltration. Inthestudygroup,themaletofemaleratiowas2.6:1.The mean age at onset was 58 years (range, 24Y83 yr). The mean delaytodiagnosis,correspondingtothedelaybetweenthefirst symptoms and the discovery of elevated IgG4 blood levels or typical histologic findings, was 3.8 years. However for some patients the delay to diagnosis was very long, up to 18 years for 1 patient. Only 6 (24%) patients presented with a history of allergic disease. Four of 25 patients presented with other associated inflammatory disease: 1 with ankylosing spondylarthritis, 1 with rheumatoid arthritis, 1 with sarcoidosis, and 1withrectocolitis. ClinicalFeatures andOrganInvolvement Theclinicalfeaturesofpatientsatpresentationarereported FIGURE1. DistributionofIgGsubclasslevelsinpatientswith inTable1.Themostfrequentsymptomswereasthenia(56%), IgG4-RSD.Thehorizontalbarsshowthegeometricalmeanand weightloss(44%),abdominalpain(40%),siccasyndrome(32% 95%confidenceinterval. and 24% for xerostomia and xerophthalmia, respectively) and cough or dyspnea (20%). Fever was uncommon (12%) but mentofmorethan1organ(range,2Y7organs)(Table3).The3 lymphadenopathy was frequent on examination (44%). All 25 patients with isolated organ involvement presented with retropatientspresentedwithtypicalorganinvolvementasshownin peritonealfibrosis(n=2)ormeningealpseudotumor(n=1). Table2.Themostcommontissuesinvolvedwerelymphnodes (76%), pancreas (52%), salivary glands (44%), kidney (44%), LaboratoryCharacteristics biliary duct (32%), and retroperitoneum (32%). As many as 6 Mean IgG and IgG subclass levels are shown in Table 4; (24%)patientspresentedwitharterialwallinflammatorylesions. agraphicrepresentationisshowninFigure1.IgG4geometrical All6hadaortitis,associatedin1casewithcoronaryinflammameanlevelwas7.2(SD3.3)g/L(range,1.4Y63.7g/L).Elevenof tory lesions and in another casewith carotid and intracerebral inflammatoryaneurysms.Mostpatientspresentedwithinvolve24 patients had elevated IgG1 levels (911.4 g/L) (range, 12.2Y36.7 g/L); 5 had elevated IgG2 levels (96.4 g/L) (range, 7.31Y39.5 g/L); and 9 had elevated IgG3 levels (91.1 g/L) (range,1.13Y19.5g/L).Only3patientspresentedwithallIgG TABLE4. LaboratoryCharacteristicsofPatientsWith subclasses elevated (Patients 6, 13, 25). Patient 17, with assoIgG4-RSD* ciatedsarcoidosis,hadonlymildIgG1elevatedlevels(14.5g/L) with normal IgG2 and IgG3 levels.Analysis by the Spearman Value correlation test of patients’ IgG4 levels showed no correlation (n=25) with IgG1 (p = 0.58) and IgG2 (p = 0.36), but a positive correlationwithIgG3levels(p=0.03,r=0.43).PolyclonalhyperIgG(g/L) 25.5(1.8) gammaglobulinemia on standard serum protein electrophoresis IgG4(g/L) 7.2(3.3) wasnoticedin80%(20/25),andhyperproteinemia(980g/L)in IgG1(g/L) 12.1(1.8) 48% (12/25) of the cases. IgE levels were elevated in 2 of 5 IgG2(g/L) 4.0(2.4) analyzed patients. Antinuclear antibodies were positive at diluIgG3(g/L) 1.1(3.2) tionsover1:100in4of25patients.Noneofthe23patientsexLowCH50 33%(5/15) aminedhadanti-SSAoranti-SSBantibodies.ElevatedC-reactive LowC3 44%(7/16) proteinlevels(910mg/L)wereobservedin56%,withameanof LowC4 40%(6/15) 30.89 mg/L (range, 11Y148 mg/L). C3 and/or C4 complement ANA 16%(4/25) fraction serum levels were decreased in 9 of the 16 analyzed A-SSA 0%(0/23) patients.Ofthese,7hadnephritis. A-SSB 0%(0/23) HistologicFindings ElevatedIgE(9100kUI/L) 40%(2/5) For all patients at least 1 histologic tissue examination ElevatedCRP(910mg/L) 56%(14/25) wasperformed(range,1Y4differenttissuebiopsiesperpatient). Abbreviations:ANA=antinuclearantibodies,A-SSA=anti-SS-A/Ro Resultsofconventionalhistologicexaminationonhematoxylinantibodies,A-SSB=anti-SS-B/Laantibodies,CH50=50%hemolyticunit eosin and/or Masson trichrome staining were available for ofcomplement,CRP=C-reactiveprotein. all, but immunofluorescence or immunohistochemical staining *Valuesareprovidedasgeometricalmeans(geometricalSD)forIgG, withanti-IgG4mAbwasperformedinonly12patients.Table5 IgG1,IgG2,IgG3,andIgG4.Incidencerates(numbersofpositivepatients) depicts the histologic findings for each tissue analyzed. Taken areshownforANA,A-SSA,A-SSB;elevatedIgE,elevatedCRP;andlow together, lymphocytic infiltration and polyclonal plasma cell CH50,C3,andC4.IgE,A-SSA,A-SSB,andCH50/C3/C4wereexamined infiltration were the most frequent findings, each in 92% of in5,23,23,and15/16/15patients,respectively(notall). patients.Fibrosiswasnoticedin80%andextranodallymphoid 52 www.md-journal.com *2012LippincottWilliams&Wilkins
& Medicine Volume91,Number1,January2012 NationwideStudyofIgG4-RelatedSystemicDisease TABLE5. HistologicResultsfor25IgG4-RSDPatients* Lymphocytic LymphoidFollicle PolyclonalPlasmocyte N Organ Fibrosis Infiltration Formation Infiltration ImmunohistologicStaining 1 Liver +++ + + No NA Kidney ++ +++ + +++ IgG4++ 2 LG ++ ++ +++ ++ NA SG ++ ++ No + NA LN No FH NA 3 RPF ++ No No ++ NA 4 Meningeal ++ + + +++ IgG4+plasmacells+++ 5 Kidney ++ ++ No +++ IgG4+plasmacells+++ SG ++ ++ No No NoIgG4+plasmacell 6 LN No IF++ NA Bileduct ++ ++ No ++ NA Pancreas +++ ++ No ++ NA 7 SG +++ ++ + ++ NA Pancreas ++ ++ No ++ NA Bileduct ++ ++ No ++ NA 8 RPF +++ ++ No ++ 9 Parotid No + ++ ++ NopredominantIgG4expression Liver + + No No NA Pancreas ++ No No No NA 10 Pleura ++ ++ No No NA Thyroid ++ ++ No No NA 11 Liver + + No No NA Bileduct ++ ++ No + NA 12 Pancreas +++ ++ + +++ NA Aorticwall ++ ++ No ++ NA LN No FH IF++ NA SG + +++ ++ No NA 13 Liver ++ ++ No ++ NA LN ++ FH IF++ IgG4+plasmacells+++ Bileduct + ++ No + NA 14 LN No FH IF++ NA Kidney No ++ No +++ NA 15 LN ++ FH IF++ IgG3+andIgG4+plasmacells+++ Kidney No + No +++ IgG3+andIgG4+plasmacells+++ SG ++ ++ ++ + NA 16 SG No + No +++ NA Parotid No ++ No + NA LN No FH IF NA 17 SG ++ ++ No No NA LN No EF No NA Pancreas +++ + No + NA 18 SG ++ ++ ++ + IgG4staining+butnoIgG4+plasmacells Kidney +++ + ++ +++ IgA+plasmacells+++,IgMplasmacells++ 19 SG No ++ ++ No NA FRP NA NA NA NA NA 20 LN No +++(9150/hpf) IgG4+plasmacells+++(60%) SG No No No No NA RPF NA NA NA NA NA 21 LN NA NA NA NA NA Pancreas ++ + No + NA 22 Kidney +++ +++ No +++ IgG4+plasmacells+++andIgA+plasmacells++ Liver + + No + NA Pancreas ++ ++ + ++ NA LN + FH No (Continuedonnextpage) 53 *2012LippincottWilliams&Wilkins www.md-journal.com
& Ebboetal Medicine Volume91,Number1,January2012 TABLE5.(Continued) Lymphocytic LymphoidFollicle PolyclonalPlasmocyte N Organ Fibrosis Infiltration Formation Infiltration ImmunohistologicStaining 23 SG No +++ ++ No NA Nasalmucosa No ++ No No NA Bronchial No ++ No ++ NA mucosa Stomach No ++ No ++ NA Ileum No ++ ++ No NA Colon + + No + NA Nasalmucosa 24 SG ++ +++ ++ ++ IgG4+plasmacells+++ 25 PararenalIPT +++ + + +++ IgG4+plasmacells++(50/hpf) Kidney +++ ++ + ++ IgG4+plasmacells++(50/hpf) SG + + No No NA Abbreviations:EF=epithelioidfollicles,FH=follicularhyperplasia,hpf=high-powerfield,IF=interfollicularinfiltration,IPT=inflammatory pseudotumor,LG=lachrimalgland,LN=lymphadenopathy,N=patientnumber,NA=datanotavailable,RPF=retroperitonealfibrosis,SG=salivary gland. *Scale:no=notpresent,present(+),abundant(++),orintense(+++). follicle formation in52%ofpatients. Thedegree ofthese his- and lymph node biopsy showed diffuse infiltration by both tologicchangeswasvariableinthesamepatientdependingon IgG4+andIgG3+plasmacells.Bonemarrowbiopsywaspertheorgananalyzed.Stainingwith ananti-IgG4mAbontissue formedin13patientsandwasnormalin7(54%).In2patients sections was performed in only 12 of 25 patients; 8 showed apolyclonalmaturelymphocyticinfiltrationwasobserved,and numerous IgG4+ plasma cells. In 1 patient (Patient 9) IgG4+ polyclonalplasmacellinfiltrationwasnotedin6patients,butno plasma cells were detected but did not predominate among IgG4+stainingwasavailable. IgG+plasmacells.Inanotherpatient,thesalivaryglandlacked IgG4+plasmacells(Patient18).InPatient18,whopresented Follow-UpandResponsetoTreatment withtypicalrenalinterstitiallymphoidandplasmacellinfiltra- Patientfollow-upandhistorieswererecordedwithamean tion with extensive storiform fibrosis, IgG4+ and IgG+ cells follow-up of 60.4 months (range, 4Y224 mo). Only 1 patient werenotdetecteddespiteserumIgG4throughlevelsof20.6g/L. (Patient 10) died, from a probable rupture of thoracic aortic Inthispatient,furtherimmunostainingwithanti-IgAandanti- aneurysm.TreatmentsareshowninTable6.Treatmentefficacy IgM mAbs showed diffuse infiltration with IgA+ plasma cells was determined based on clinical, laboratory, and radiologic and, to a lesser extent, with IgM+ plasma cells. Staining for global evaluation by the physician. Most patients (92%, n = immunoglobulin light chains with an anti-kappa and an anti- 23) received prednisone (median, 0.6 mg/kg per d; mean, lambda mAb showed a polyclonal pattern, and bone marrow 0.67 mg/kg per d, SD = 0.3; range, 0.12Y1). Two patients biopsywasnormal.SerumIgAandIgMlevelswerenormalin did not receive prednisone as a consequence of mild disease thispatient.Inanotherpatient(Patient15)withincreasedIgG4 (Patient 6) or contraindication to steroids (Patient 15, pulmoand IgG3 blood levels, immunohistologic analysis on kidney narytuberculosisundertreatmentandchronicosteitis).Efficacy TABLE6. TreatmentandEfficacy PatientsTreated TreatmentEffective SideEffects Treatment No.(%) No.(%) No.(%) Corticosteroids 23(92) 19/21*(90) 14/21*(67) Azathioprine 6(24) 3/4*(75) 1/4*(25) Rituximab 3(12) 2/3(67) 0/3(0) Cyclophosphamide 3(12) 1/3(33) 1/3(33) Methotrexate 2(8) 1/2(50) 0/2(0) Other Surgery 4(16) 1/4(25) 1/4(25) Hepatictransplantation 1(4) 0/1(0) 1/1(100) Vinblastine 2(8) 0/2(0) 0/2(0) Tamoxifen 1(4) 0/1(0) 1/1(100) Tocilizumab 1(4) 1/1(100) 0/1(0) Imatinib 1(4) 0/1(0) 0/1(0) *Recenttreatmentfor2patients,responseandtolerancenotyetevaluable. 54 www.md-journal.com *2012LippincottWilliams&Wilkins
& Medicine Volume91,Number1,January2012 NationwideStudyofIgG4-RelatedSystemicDisease wasnoticedin90%ofcases.Corticosteroidscouldbestopped ranging from 1.4 to 63.7 g/L. Remarkably high IgG4 levels in 30% of treated patients. Second-line treatments were used werefoundespeciallyinpatientswithinterstitialnephritis.There in12(48%)patientsbecauseofsteroiddependenceand/orste- wasnocorrelationbetweenserumIgG4,IgG1,andIgG2levels, roid side effects (n = 10), or because of insufficient response but there was a positive correlation between IgG4 and IgG3 under steroids (n = 2). Azathioprine was used in 6 patients. levels.Inonly3cases,allIgGsubclasseswereincreased.IgG4 Rituximab was used in 3 patients, with an estimated good re- andIgG3levelsweresignificantlyhigherinIgG4-RSDpatients sponsein2(Patients16,20)andnoresponsein1(Patient14). withrenalinvolvementthaninIgG4-RSDpatientswithoutrenal (For more about rituximab treatment for IgG4-RSD, see the involvement(p=0.0048andp=0.0034,respectively).MorearticlebyKhosroshahietal10ainthissameissue.)Cyclophos- over,in7/8(88%)patientswithinterstitialnephritis,C3and/or phamide was used in 3 patients, methotrexate in 2, imatinib C4complementfractionsweredecreased(only29%ofpatients in1,andtocilizumabin1. withoutrenal involvement).A highfrequencyofhypocomplementemiawas already reported in IgG4-RSD tubulointerstitial nephritis.15AsIgG4doesnotactivatethecomplementclassical DISCUSSION pathway,thesefindingsmaysuggestthatIgG3couldparticipate We report here 25 patients with IgG4-RSD recorded in a inimmunecomplexformation. Frenchnationalregistry.Todatenowell-recognizedinternational Some of our patients presented with atypical findings on diagnosis criteria for IgG4-RSD have been defined. Numerous immunohistologydespite‘‘typical’’histologicabnormalitieson reports indicate that the association of high serum IgG4 levels conventional hematoxylin-eosin staining. In 3 patients immuwith organ infiltration by polyclonal lymphocytes and IgG4+ nohistologicanalysisofplasmacellinfiltrationwassurprising. plasma cells enables IgG4-RSD to be distinguished from well- InPatient15,IgG4+plasmacellswereassociatedwithnumercharacterizedautoimmuneorinflammatorydisease,lymphopro- ousIgG3+plasmacellsinlymphnodeandkidney;inPatient22, liferative malignant diseases, and other conditions previously numerousIgA+plasmacellswereassociatedwithIgG4+plasma associated with increased IgG4 levels.11 We have included in cellsintherenalinterstitium,andinPatient18onlyIgA+and the current study only patients presenting with IgG4 serum IgM+plasmacellswerefoundinthekidney.Theobservations levels 91.35 g/L associated with ‘‘classical’’ organ involvement thatotherIgGsubclassesarealsoelevatedinthebloodofmore with fibrosis and polyclonal lymphocytic and plasma cell infil- thanhalfthepatients,andthatnumerousinfiltratingplasmacells trationwithoutevidenceofotherdiseases.Ofnote,noneofthe actually express Ig isotypes other than IgG4, indicate a more patients presented with anti-SSA or anti-SSB, and only 4 had broadpolyclonalBlymphocyteactivationthantheskewedIgG4 low titers of antinuclear autoantibodies. Unfortunately, in this switch reported to date in IgG4-RSD. However most tissues retrospective multicentric study the immunohistologic analysis analyzedinthecurrentstudywithananti-IgG4+mAbshowed for IgG4+ plasma cell infiltration was lacking for a significant abundantIgG4+plasmacells(8/12).Thesefindingsconfirmthe number of patients. Moreover, when performed, no accurate importanceofcharacterizingalltheimmunoglobulinisotypesof quantitativeanalysisforIgG4+plasmocyteinfiltrationwasavail- theplasmacellinfiltrationinIgG4-RSDtoclarifytheseobserable in most cases. However all the patients satisfied the clini- vationsandthenatureofplasmocyteinfiltrationinIgG4-RSD. cal and laboratory (IgG4 91.35) criteria as recently proposed.13 Fivepatientswereexcludedfromthecurrentseriesbecause All patients were shown to have characteristic pathologic find- of the lack of available pathologic analysis despite elevated ingswitheitherpolyclonalplasmacelland/orlymphocyticinfil- IgG4levelsandtypicalorganinvolvement.Pathologicfeatures tration(100%)orstoriformfibrosis(80%). in our patients also showed that the degree or the presence of Males were significantly more frequent in our cohort lymphocyticandplasmacellinfiltrationandfibrosiscouldvary (18 of 25 patients). Allergic conditionswere noticed inonlya withinthesamepatientdependingonthetissueanalyzed.The fewof our patients despite a high frequencyinsome previous usualabsenceoffibrosisinlymphnodeswasnotsurprisingand cohorts.11 Lymph node enlargement on examination was the was in accordance with previous reports. Some patients premostfrequentsign,which mightsuggestaprimarydefectthat sented with typical clinical organ involvement and typical couldinvolvesecondarylymphoidevents. pathologicfeaturesincludingIgG4+plasmacellinfiltrationbut As noted previously, xerostomia was less frequent (32%) normal IgG4 blood levels (n = 3). These patients were exthanexpectedconsideringthefrequencyofsialadenitis(44%).11 cludedfromthestudybutraisethequestionoftheimportance Mostpatientspresentedwithmultipleorganinvolvement.Organ accorded to the elevation of IgG4 in blood for the diagnosis involvementinthecurrentseriesisinaccordancewithprevious ofIgG4-RSD.Infact,thesepatientsprobablypresentedwitha reports with lymph node (76%), pancreas (52%), and salivary ‘‘seronegative’’IgG4-RSDasproposedintheclinicaldiagnosglands(44%)involvementasthemostfrequentmanifestations. tic criteria for IgG4-RSD proposed by the Japanese Research Inthecurrentstudyrenalinvolvementwasrelativelymorefre- Committeefor‘‘systemicIgG4-relatedsclerosingdisease’’.13 quent (44%) than previously reported in IgG4-RSD (17%).11 Thecurrentretrospectiveanalysisofresponsetotreatment Sclerosing cholangitis was less frequent (32%). The observed in patients with IgG4-RSD was based on very basic response differences maybe related tothepatients’recruitment through criteriathatdidnotallowstrongconclusions.Weobservedthe the registry. Moreover it must be taken in account that IgG4- efficacy of corticosteroids in IgG4-RSD, but also the frequent RSDisunder-recognized,andthatpatientsincludedinthereg- need for second- or third-line treatments. This indicates the istryarethoseprobablypresentingwithaseveredisease,which urgent need for a better understanding of the pathogenesis mayaccountforthehighfrequencyofmultipleorganinvolve- of IgG4-RSD to help define new and more specific therament observed. Of note, 6 patients presented with aortitis, as- peutic strategies. Importantly, it is still unknown whether sociated with otherarterialinflammatorylesions in2ofthem. IgG4-secreting plasma cells merely result from an upstream This confirms the association of IgG4-RSD with large-vessel pathogenic immunologic event,or if theydo participate in the vasculitis,asrecentlyreported.10,17,18 pathogenesis. Our findings also suggest direct or indirect imLaboratoryfindingsfor patientsinthecurrentstudywere plication of other Ig classes and subclasses in the disease. To comparabletothosereportedpreviouslyinpatientswithIgG4- date only a few studies have analyzed modifications of T-cell RSD. Elevation of serum IgG4 levels was extremely variable, subsetsinIgG4-RSD.4Thelper2(Th2)andregulatoryTcells 55 *2012LippincottWilliams&Wilkins www.md-journal.com
& Ebboetal Medicine Volume91,Number1,January2012 were demonstrated in tissues and in the blood from some of 10a.KhosroshahiA,CarruthersMN,DeshpandeV,UnizonyS, these patients.3,20,21 Other T-cell subsets, such as follicular BlochDB,StoneJH.RituximabforthetreatmentofIgG4-related helperTcells,maycertainlyparticipate inthepathogenesisof disease:lessonsfrom10consecutivepatients.Medicine(Baltimore). IgG4-RSD by enhancing Ig isotype switching and B-cell ter- 2012;91:57Y66. minaldifferentiation.Furtherclinical,laboratory,andhistologic 11. MasakiY,DongL,KuroseN,KitagawaK,MorikawaY,YamamotoM, studies are needed to better define IgG4-RSD and tovalidate TakahashiH,ShinomuraY,ImaiK,SaekiT,AzumiA,NakadaS, diagnosticcriteria. SugiyamaE,MatsuiS,OriguchiT,NishiyamaS,NishimoriI,NojimaT, YamadaK,KawanoM,ZenY,KanekoM,MiyazakiK,TsubotaK, EguchiK,TomodaK,SawakiT,KawanamiT,TanakaM,FukushimaT, ACKNOWLEDGMENT SugaiS,UmeharaH.Proposalforanewclinicalentity,IgG4-positive We thank Karine Barrau-Baumstark for herassistance in multiorganlymphoproliferativesyndrome:analysisof64casesof thestatisticalanalysis. IgG4-relateddisorders.AnnRheumDis.2009;68:1310Y1315. 12. OkazakiK,KawaS,KamisawaT,NaruseS,TanakaS,NishimoriI, OharaH,ItoT,KiriyamaS,InuiK,ShimosegawaT,KoizumiM, REFERENCES SudaK,ShiratoriK,YamaguchiK,YamaguchiT,SugiyamaM, 1. AalberseRC,DiegesPH,Knul-BretlovaV,VoorenP,AalbersM, OtsukiM.Clinicaldiagnosticcriteriaofautoimmunepancreatitis: vanLeeuwenJ.IgG4asablockingantibody.ClinRevAllergy. revisedproposal.JGastroenterol.2006;41:626Y631. 1983;1:289Y302. 13. OkazakiK,UchidaK,KoyabuM,MiyoshiH,TakaokaM.Recent 2. AalberseRC,StapelSO,SchuurmanJ,RispensT.ImmunoglobulinG4: advancesintheconceptanddiagnosisofautoimmunepancreatitisand anoddantibody.ClinExpAllergy.2009;39:469Y477. IgG4-relateddisease.JGastroenterol.2011;46:277Y288. 3. AkitakeR,WatanabeT,ZaimaC,UzaN,IdaH,TadaS,NishidaN, 14. OtsukiM,ChungJB,OkazakiK,KimMH,KamisawaT,KawaS, ChibaT.PossibleinvolvementofThelpertype2responsestoToll-like ParkSW,ShimosegawaT,LeeK,ItoT,NishimoriI,NotoharaK, receptorligandsinIgG4-relatedsclerosingdisease. NaruseS,KoSB,KiharaY.Asiandiagnosticcriteriaforautoimmune Gut.2010;59:542Y545. pancreatitis:consensusoftheJapan-KoreaSymposiumonAutoimmune Pancreatitis.JGastroenterol.2008;43:403Y408. 4. BoulangerE,FuentesV,MeigninV,MougenotB,LabaumeS, Gouilleux-GruartV,CogneM,AucouturierP,ClauvelJP,RoncoP, 15. SaekiT,NishiS,ImaiN,ItoT,YamazakiH,KawanoM,YamamotoM, LassouedK.PolyclonalIgG4hypergammaglobulinemiaassociated TakahashiH,MatsuiS,NakadaS,OriguchiT,HirabayashiA, withplasmacyticlymphadenopathy,anemiaandnephropathy. HommaN,TsubataY,TakataT,WadaY,SaitoA,FukaseS,IshiokaK, AnnHematol.2006;85:833Y840. MiyazakiK,MasakiY,UmeharaH,SugaiS,NaritaI. ClinicopathologicalcharacteristicsofpatientswithIgG4-related 5. CheukW,YuenHK,ChuSY,ChiuEK,LamLK,ChanJK. tubulointerstitialnephritis.KidneyInt.2010;78:1016Y1023. LymphadenopathyofIgG4-relatedsclerosingdisease. AmJSurgPathol.2008;32:671Y681. 16. SarlesH,SarlesJC,MuratoreR,GuienC.Chronicinflammatory sclerosisofthepancreasVanautonomouspancreaticdisease? 6. ChoiEK,KimMH,LeeTY,KwonS,OhHC,HwangCY,SeoDW, AmJDigDis.1961;6:688Y698. LeeSS,LeeSK.Thesensitivityandspecificityofserum immunoglobulinGandimmunoglobulinG4levelsinthediagnosis 17. StoneJH,KhosroshahiA,DeshpandeV,StoneJR.IgG4-related ofautoimmunechronicpancreatitis:Koreanexperience. systemicdiseaseaccountsforasignificantproportionofthoracic Pancreas.2007;35:156Y161. lymphoplasmacyticaortitiscases.ArthritisCareRes(Hoboken). 2010;62:316Y322. 7. GhazaleA,ChariST,SmyrkTC,LevyMJ,TopazianMD,TakahashiN, ClainJE,PearsonRK,Pelaez-LunaM,PetersenBT,VegeSS, 18. StoneJH,KhosroshahiA,HilgenbergA,SpoonerA,IsselbacherEM, FarnellMB.ValueofserumIgG4inthediagnosisofautoimmune StoneJR.IgG4-relatedsystemicdiseaseandlymphoplasmacytic pancreatitisandindistinguishingitfrompancreaticcancer. aortitis.ArthritisRheum.2009;60:3139Y3145. AmJGastroenterol.2007;102:1646Y1653. 19. vanderNeutKolfschotenM,SchuurmanJ,LosenM,BleekerWK, 8. HamanoH,KawaS,HoriuchiA,UnnoH,FuruyaN,AkamatsuT, Martinez-MartinezP,VermeulenE,denBlekerTH,WiegmanL, FukushimaM,NikaidoT,NakayamaK,UsudaN,KiyosawaK. VinkT,AardenLA,DeBaetsMH,vandeWinkelJG,AalberseRC, HighserumIgG4concentrationsinpatientswithsclerosingpancreatitis. ParrenPW.Anti-inflammatoryactivityofhumanIgG4antibodies NEnglJMed.2001;344:732Y738. bydynamicFabarmexchange.Science.2007;317:1554Y1557. 9. KamisawaT,OkamotoA.IgG4-relatedsclerosingdisease. 20. ZenY,FujiiT,HaradaK,KawanoM,YamadaK,TakahiraM, WorldJGastroenterol.2008;14:3948Y3955. NakanumaY.Th2andregulatoryimmunereactionsareincreasedin immunoglobinG4-relatedsclerosingpancreatitisandcholangitis. 10. KasashimaS,ZenY,KawashimaA,EndoM,MatsumotoY, Hepatology.2007;45:1538Y1546. KasashimaF,OhtakeH,NakanumaY.Aclinicopathologicstudy ofimmunoglobulinG4-relatedsclerosingdiseaseofthethoracicaorta. 21. ZenY,NakanumaY.PathogenesisofIgG4-relateddisease. JVascSurg.2010;52:1587Y1595. CurrOpinRheumatol.2011;23:114Y118. 56 www.md-journal.com *2012LippincottWilliams&Wilkins